جميع الدراسات
التوظيفالمرحلة 3تدخلي

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

This study is for adults with a condition called Immune Thrombocytopenia (ITP). ITP causes your body to destroy tiny blood cells called platelets, which help your blood clot. This can lead to bruising and bleeding easily. We are trying to find out if a new medicine called mezagitamab can help keep platelet counts stable in people with ITP. Participants will receive either mezagitamab or a dummy medicine (placebo) by injection under the skin for up to 6 months. We then look at how each group's platelet counts change. Some people might also have the chance to continue taking mezagitamab after the main study ends.

نظرة سريعة

الحالة
التوظيف
المرحلة
المرحلة 3
الراعي
Takeda
الهدف من التسجيل
171
ابدأ
٢٧ فبراير ٢٠٢٥
التاريخ المتوقع للانتهاء
16 Mar 2028

ما هو موضوع هذه الدراسة؟

This study is focused on a condition called Immune Thrombocytopenia, or ITP. If you have ITP, your body's defence system, called the immune system, mistakenly attacks and destroys your platelets. Platelets are really important because they are tiny cells in your blood that help it to clot and stop bleeding. When you don't have enough platelets, you might bruise easily, notice small red spots on your skin, or experience nosebleeds or gum bleeding.

We are looking into a new medicine called mezagitamab. The main goal of this study is to see if mezagitamab can effectively help keep your platelet count at a healthy and stable level compared to a placebo. A placebo looks exactly like the real medicine but doesn't contain any active ingredients. This helps us understand if any improvements are truly due to the new medicine.

Participants in the study will receive mezagitamab or the placebo as an injection just under the skin. This treatment will continue for up to six months. We hope this study will give us important information about whether mezagitamab could be a helpful new treatment option for people living with ITP.

النقاط الرئيسية

  • This study is testing a new medicine (mezagitamab) for adults with ITP.
  • It aims to see if mezagitamab can help keep platelet counts stable.
  • You might receive the new medicine or a dummy treatment (placebo).
  • Treatment is given by injection under the skin for up to 6 months.
  • Regular clinic visits are required to monitor your health.
  • There's a chance to continue with mezagitamab after the main study, if eligible.

من قد يكون مؤهلاً؟

This study is for adults aged 18 and over who have been diagnosed with ITP for at least a year. You would need to have shown a good response to an ITP treatment in the past (but not a type called a TPO-RA), and your current platelet count should be less than 30,000.

You also need to have tried and not responded well to or couldn't tolerate at least two different types of ITP treatment – one first-line treatment (like steroids) and at least one second-line treatment (like TPO-RAs, rituximab, fostamatinib, or mycophenolate). If you're using other ITP treatments, they need to have been at a steady dose for at least a month before the study starts and expected to stay the same throughout.

You wouldn't be able to join if your ITP is due to another medical condition (called secondary ITP), if you've had a blood clot or stroke in the last year, have had your spleen removed, or have certain active infections like Hepatitis B, C, or HIV. A history of certain cancers would also mean you couldn't take part.

هل يمكن أن تناسبك هذه الدراسة؟

أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.

  1. عمري 18 عامًا أو أكثر.
  2. I have been diagnosed with ITP for at least one year.
  3. My current platelet count is less than 30,000.
  4. I have tried at least two different ITP treatments (like steroids and another type) in the past, and they either didn't work well enough or caused too many side effects.
  5. I have not had a blood clot or stroke in the past year.
  6. I do not have Hepatitis B, C, or HIV.
أجب عن كل سؤال لترى نتيجتك.

ماذا يتضمن المشاركة؟

If you join the study, you'll receive the study medicine (mezagitamab or a placebo) as an injection under your skin for up to 6 months. Throughout this time, you'll need to visit the study clinic several times. These visits will involve checks to see how you are doing, including blood tests to measure your platelet count and general health. The doctors will also ask you questions about any side effects you might be experiencing.

After the main study finishes, or if the treatment doesn't seem to be working for you after 16 weeks, you may get the chance to join a follow-on study. In this continuation study, eligible participants would receive mezagitamab openly, meaning they would know they are getting the active medicine. The doctors will explain more about this if it applies to you.

المخاطر والفوائد المحتملة

Taking part in a clinical trial can have potential benefits, like gaining access to a new medicine before it's widely available, and helping doctors learn more about ITP and its treatment. However, there are also potential risks, such as side effects from the medicine or the extra clinic visits required. You might receive the placebo, which means you won't get the active study drug. Your health will be carefully monitored throughout the study, and you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (124)

  • Genesis Cancer and Blood Institute - SCRI
    الرمز البريدي المؤكد
    هوت سبرينغز، الولايات المتحدة· التوظيف
  • USC Norris Comprehensive Cancer Center - Keck Medicine of USC
    الرمز البريدي المؤكد
    لوس أنجلوس، الولايات المتحدة· التوظيف
  • University of California San Diego Center for Bleeding and Clotting Disorders
    الرمز البريدي المؤكد
    سان دييغو، الولايات المتحدة· لم يبدأ التوظيف بعد
  • مركز روكي ماونتن للسرطان
    الرمز البريدي المؤكد
    دنفر، الولايات المتحدة· منسحب
  • Georgetown University Medical Center - Lombardi Comprehensive Cancer Center
    الرمز البريدي المؤكد
    واشنطن العاصمة، الولايات المتحدة· التوظيف
  • جامعة إيموري
    الرمز البريدي المؤكد
    أتلانتا، الولايات المتحدة· التوظيف
  • Innovative Hematology, Inc.
    الرمز البريدي المؤكد
    إنديانابوليس، الولايات المتحدة· التوظيف
  • The University of Iowa
    الرمز البريدي المؤكد
    مدينة آيوا، الولايات المتحدة· التوظيف
  • University Of Louisville Brown Cancer Center
    الرمز البريدي المؤكد
    لويفيل، الولايات المتحدة· التوظيف
  • American Oncology Partners of Maryland, PA
    الرمز البريدي المؤكد
    بيثيسدا، الولايات المتحدة· التوظيف
  • مستشفى ماساتشوستس العام
    الرمز البريدي المؤكد
    بوسطن، الولايات المتحدة· التوظيف
  • University of Massachusetts Chan Medical School
    الرمز البريدي المؤكد
    وورسيستر، الولايات المتحدة· مكتمل

أسئلة شائعة

What is ITP?

ITP (Immune Thrombocytopenia) is a condition where your immune system mistakenly destroys your platelets, which are tiny cells that help your blood clot. This can lead to easy bruising and bleeding.

What is mezagitamab?

Mezagitamab is the new medicine being tested in this study. We want to see if it can help keep platelet counts stable in people with ITP.

ما هو الدواء الوهمي؟

A placebo is a dummy medicine. It looks exactly like the study medicine but contains no active ingredients. It helps doctors work out if the real medicine is having an effect.

كيف سأستلم الدواء الخاص بالدراسة؟

The study medicine (mezagitamab or placebo) will be given as an injection just under your skin.

كم من الوقت سأكون في الدراسة؟

You will receive the study medicine for up to 6 months, and there will be several follow-up visits during and after this period.

كيفية معرفة المزيد

اتصل بتاكيدا

تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.

هل أنت مهتم بالمشاركة؟

سجل اهتمامك

شارك تفاصيلك وفريق البحث لـ "A Study of Mezagitamab in Adults With Chronic Primary Immune… "سيتواصل معك إذا كنت مؤهلاً. تحدث دائمًا إلى طبيبك قبل الموافقة على المشاركة.

نقاش

مناقشة المجتمع

مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.